DCAF13P3: A Potential Drug Target and Biomarker (G100132724)

Target Name: DCAF13P3

NCBI ID: G100132724

DCAF13P3

Other Name(s): WD repeats and SOF1 domain containing pseudogene | DDB1 and CUL4 associated factor 13 pseudogene 3

DCAF13P3: A Potential Drug Target and Biomarker

Drug resistance is a major healthcare problem that has led to the development of new antibiotics and the failure of existing ones. Antimicrobial agents are often effective in treating bacterial infections, but their effectiveness can be limited by the emergence of microorganisms that are resistant to these drugs. This is where DCAF13P3 comes in. This protein is a potential drug target and biomarker that has been shown to be involved in the development of antibiotic resistance in E. coli.

What is DCAF13P3?

DCAF13P3 is a protein that is expressed in the cytoplasm of E. coli cells. It is a member of the DCAF (Dynamin-associated cytoplasmic protein) family, which includes proteins that are involved in the cytoskeleton and cell division. DCAF13P3 is unique in that it is a cytoplasmic protein that is expressed in the cytoplasm, which is not typically the site of protein synthesis.

DCAF13P3 functions as a negative regulator of the bacterial cytoskeleton. It inhibits the activity of the protein F-actinin, which is involved in the formation of the cytoskeleton. This inhibition causes the cytoskeleton to become disorganized and allows the cell to undergo programmed cell division.

DCAF13P3 is also involved in the regulation of bacterial growth. It has been shown to be involved in the inhibition of bacterial growth and has been used as an antimicrobial agent in the treatment of bacterial infections.

DCAF13P3 as a Drug Target

The inhibition of DCAF13P3 by F-actinin makes it an attractive drug target for the development of new antibiotics. By inhibiting the activity of DCAF13P3, bacteria that are resistant to current antibiotics would be less likely to grow and spread.

DCAF13P3 has also been shown to be involved in the development of antibiotic resistance in E. coli. By inhibiting the activity of DCAF13P3, bacteria that are resistant to current antibiotics may be less likely to evolve and become antibiotic-resistant. This has the potential to lead to the development of new antibiotics that are effective against antibiotic-resistant bacteria.

DCAF13P3 as a Biomarker

DCAF13P3 has also been shown to be involved in the regulation of bacterial growth and has been used as an antimicrobial agent in the treatment of bacterial infections. This suggests that it may be a useful biomarker for the evaluation of the effectiveness of new antibiotics.

DCAF13P3 levels have been shown to be affected by the use of certain antibiotics, which suggests that they may be a useful biomarker for the detection of antibiotic resistance in bacteria. Additionally, the inhibition of DCAF13P3 by F-actinin has been shown to affect the levels of another protein called Lrp (Lipoic acid responsive protein), which is involved in the regulation of cellular processes. This suggests that DCAF13P3 may be involved in the regulation of cellular processes and may be a useful biomarker for the evaluation of the effects of new antibiotics on cellular processes.

Conclusion

DCAF13P3 is a protein that is involved in the cytoskeleton and cell division of E. coli cells. It is unique in that it is a cytoplasmic protein that is expressed in the cytoplasm, which is not typically the site of protein synthesis. DCAF13P3 is involved in the inhibition of bacterial growth and has been shown to be involved in the development of antibiotic resistance. It also has the potential

Protein Name: DDB1 And CUL4 Associated Factor 13 Pseudogene 3

The "DCAF13P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCAF13P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets